Case study – HEOR strategies and impact on cost-effectiveness for gene therapy in spinal muscular atrophy (SMA) Gene therapies have leapt from laboratory promise to bedside reality, yet a single dose can cost more than €2 million. For publicly funded health systems, clinical efficacy alone no longer unlocks coverage; budgets must also survive. That is […]
